Tags

Type your tag names separated by a space and hit enter

Advances in the management of MS symptoms: real-life evidence.
Neurodegener Dis Manag. 2015; 5(6 Suppl):19-21.ND

Abstract

Once the efficacy and tolerability of a new intervention have been demonstrated in clinical trials under ideal experimental conditions, observational studies within approved label conditions are performed to determine its effectiveness in real-world use and expand the safety/tolerability data. Several large observational studies have been conducted of Sativex(®) (THC:CBD) oromucosal spray as add-on therapy for moderate-to-severe treatment-resistant multiple sclerosis (MS) spasticity. Studies performed to date with a focus on tolerability have confirmed the absence of abuse, misuse, addiction and lack of impairment of cognition or driving ability. Open-label studies performed to date with a focus on effectiveness have indicated that about one-half to two-thirds of patients initiated on THC:CBD oromucosal spray continue to derive benefit after 3 months' treatment at a mean dosage of 5-7 sprays/day.

Authors+Show Affiliations

Department of Basic Clinical Sciences, Neurosciences and Sense Organs, University of Bari, Italy, Policlinico di Bari, Piazza Giulio Cesare, 11 Zip-code 70124, Bari, Italy.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

26611267

Citation

Trojano, Maria. "Advances in the Management of MS Symptoms: Real-life Evidence." Neurodegenerative Disease Management, vol. 5, no. 6 Suppl, 2015, pp. 19-21.
Trojano M. Advances in the management of MS symptoms: real-life evidence. Neurodegener Dis Manag. 2015;5(6 Suppl):19-21.
Trojano, M. (2015). Advances in the management of MS symptoms: real-life evidence. Neurodegenerative Disease Management, 5(6 Suppl), 19-21. https://doi.org/10.2217/nmt.15.66
Trojano M. Advances in the Management of MS Symptoms: Real-life Evidence. Neurodegener Dis Manag. 2015;5(6 Suppl):19-21. PubMed PMID: 26611267.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Advances in the management of MS symptoms: real-life evidence. A1 - Trojano,Maria, PY - 2015/11/28/entrez PY - 2015/11/28/pubmed PY - 2016/9/16/medline KW - Sativex KW - THC:CBD oromucosal spray KW - effectiveness KW - multiple sclerosis KW - observational studies KW - review KW - safety KW - spasticity SP - 19 EP - 21 JF - Neurodegenerative disease management JO - Neurodegener Dis Manag VL - 5 IS - 6 Suppl N2 - Once the efficacy and tolerability of a new intervention have been demonstrated in clinical trials under ideal experimental conditions, observational studies within approved label conditions are performed to determine its effectiveness in real-world use and expand the safety/tolerability data. Several large observational studies have been conducted of Sativex(®) (THC:CBD) oromucosal spray as add-on therapy for moderate-to-severe treatment-resistant multiple sclerosis (MS) spasticity. Studies performed to date with a focus on tolerability have confirmed the absence of abuse, misuse, addiction and lack of impairment of cognition or driving ability. Open-label studies performed to date with a focus on effectiveness have indicated that about one-half to two-thirds of patients initiated on THC:CBD oromucosal spray continue to derive benefit after 3 months' treatment at a mean dosage of 5-7 sprays/day. SN - 1758-2032 UR - https://www.unboundmedicine.com/medline/citation/26611267/Advances_in_the_management_of_MS_symptoms:_real_life_evidence_ L2 - http://www.futuremedicine.com/doi/full/10.2217/nmt.15.66?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -